Cited 211 time in
Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Ji-Young | - |
| dc.contributor.author | Ko, Jin-A | - |
| dc.contributor.author | Kim, Dae Wook | - |
| dc.contributor.author | Kim, Young Min | - |
| dc.contributor.author | Kwon, Hyung-Jun | - |
| dc.contributor.author | Jeong, Hyung Jae | - |
| dc.contributor.author | Kim, Cha Young | - |
| dc.contributor.author | Park, Ki Hun | - |
| dc.contributor.author | Lee, Woo Song | - |
| dc.contributor.author | Ryu, Young Bae | - |
| dc.date.accessioned | 2022-12-26T20:21:33Z | - |
| dc.date.available | 2022-12-26T20:21:33Z | - |
| dc.date.issued | 2016-01-02 | - |
| dc.identifier.issn | 1475-6366 | - |
| dc.identifier.issn | 1475-6374 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/15723 | - |
| dc.description.abstract | Two viral proteases of severe acute respiratory syndrome coronavirus (SARS-CoV), a chymotrypsin-like protease (3CL(pro)) and a papain-like protease (PLpro) are attractive targets for the development of anti-SARS drugs. In this study, nine alkylated chalcones (1-9) and four coumarins (10-13) were isolated from Angelica keiskei, and the inhibitory activities of these constituents against SARS-CoV proteases (3CL(pro) and PLpro) were determined (cell-free/based). Of the isolated alkylated chalcones, chalcone 6, containing the perhydroxyl group, exhibited the most potent 3CL(pro) and PLpro inhibitory activity with IC50 values of 11.4 and 1.2 mu M. Our detailed protein-inhibitor mechanistic analysis of these species indicated that the chalcones exhibited competitive inhibition characteristics to the SARS-CoV 3CL(pro), whereas noncompetitive inhibition was observed with the SARS-CoV PLpro. | - |
| dc.format.extent | 8 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | TAYLOR & FRANCIS LTD | - |
| dc.title | Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.3109/14756366.2014.1003215 | - |
| dc.identifier.scopusid | 2-s2.0-84953310149 | - |
| dc.identifier.wosid | 000367555300003 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.31, no.1, pp 23 - 30 | - |
| dc.citation.title | JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | - |
| dc.citation.volume | 31 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 23 | - |
| dc.citation.endPage | 30 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
| dc.subject.keywordPlus | PAPAIN-LIKE PROTEASE | - |
| dc.subject.keywordPlus | RESPIRATORY SYNDROME CORONAVIRUS | - |
| dc.subject.keywordPlus | 3C-LIKE PROTEASE | - |
| dc.subject.keywordPlus | MAIN PROTEINASE | - |
| dc.subject.keywordPlus | PURIFICATION | - |
| dc.subject.keywordPlus | DESIGN | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordAuthor | Angelica keiskei | - |
| dc.subject.keywordAuthor | 3CL(pro) | - |
| dc.subject.keywordAuthor | chalcone | - |
| dc.subject.keywordAuthor | PLpro | - |
| dc.subject.keywordAuthor | SARS-CoV | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
